nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—TNF—psoriasis	0.433	1	CbGaD
Pomalidomide—CYP1A2—Clobetasol propionate—psoriasis	0.0527	0.146	CbGbCtD
Pomalidomide—PTGS2—Triamcinolone—psoriasis	0.0422	0.117	CbGbCtD
Pomalidomide—PTGS2—Betamethasone—psoriasis	0.0362	0.1	CbGbCtD
Pomalidomide—CYP1A2—Methoxsalen—psoriasis	0.0277	0.0769	CbGbCtD
Pomalidomide—PTGS2—Dexamethasone—psoriasis	0.021	0.0584	CbGbCtD
Pomalidomide—CYP3A4—Calcitriol—psoriasis	0.0187	0.0518	CbGbCtD
Pomalidomide—CYP3A4—Methoxsalen—psoriasis	0.0145	0.0403	CbGbCtD
Pomalidomide—ABCB1—Mycophenolate mofetil—psoriasis	0.0139	0.0386	CbGbCtD
Pomalidomide—ABCB1—Betamethasone—psoriasis	0.0119	0.0331	CbGbCtD
Pomalidomide—ABCB1—Prednisolone—psoriasis	0.0118	0.0327	CbGbCtD
Pomalidomide—ABCB1—Hydrocortisone—psoriasis	0.0112	0.031	CbGbCtD
Pomalidomide—ABCB1—Prednisone—psoriasis	0.0111	0.0309	CbGbCtD
Pomalidomide—ABCB1—Cyclosporine—psoriasis	0.0105	0.0293	CbGbCtD
Pomalidomide—CYP3A4—Cholecalciferol—psoriasis	0.00961	0.0267	CbGbCtD
Pomalidomide—CYP3A4—Mycophenolate mofetil—psoriasis	0.00833	0.0231	CbGbCtD
Pomalidomide—CYP3A4—Triamcinolone—psoriasis	0.00833	0.0231	CbGbCtD
Pomalidomide—CYP3A4—Betamethasone—psoriasis	0.00715	0.0198	CbGbCtD
Pomalidomide—CYP3A4—Prednisolone—psoriasis	0.00705	0.0196	CbGbCtD
Pomalidomide—ABCB1—Dexamethasone—psoriasis	0.00694	0.0193	CbGbCtD
Pomalidomide—CYP3A4—Hydrocortisone—psoriasis	0.00669	0.0186	CbGbCtD
Pomalidomide—CYP3A4—Prednisone—psoriasis	0.00666	0.0185	CbGbCtD
Pomalidomide—CYP3A4—Cyclosporine—psoriasis	0.00632	0.0175	CbGbCtD
Pomalidomide—ABCB1—Methotrexate—psoriasis	0.00558	0.0155	CbGbCtD
Pomalidomide—CYP3A4—Dexamethasone—psoriasis	0.00416	0.0115	CbGbCtD
Pomalidomide—Thalidomide—NFKB1—psoriasis	0.00366	0.765	CrCbGaD
Pomalidomide—Thalidomide—TNF—psoriasis	0.00112	0.235	CrCbGaD
Pomalidomide—PTGS2—Fluocinonide—Clobetasol propionate—psoriasis	0.000562	0.157	CbGdCrCtD
Pomalidomide—PTGS2—Fluocinonide—Beclomethasone—psoriasis	0.00045	0.126	CbGdCrCtD
Pomalidomide—PTGS2—Fluocinonide—Fluocinolone Acetonide—psoriasis	0.000438	0.122	CbGdCrCtD
Pomalidomide—PTGS2—Fluticasone Propionate—Clobetasol propionate—psoriasis	0.000339	0.0948	CbGdCrCtD
Pomalidomide—PTGS2—Fluticasone Propionate—Beclomethasone—psoriasis	0.000272	0.076	CbGdCrCtD
Pomalidomide—PTGS2—Fluticasone Propionate—Fluocinonide—psoriasis	0.000272	0.076	CbGdCrCtD
Pomalidomide—PTGS2—Fluticasone Propionate—Fluocinolone Acetonide—psoriasis	0.000264	0.0738	CbGdCrCtD
Pomalidomide—PTGS2—Fluocinonide—Dexamethasone—psoriasis	0.000205	0.0574	CbGdCrCtD
Pomalidomide—PTGS2—Fluocinonide—Betamethasone—psoriasis	0.000205	0.0574	CbGdCrCtD
Pomalidomide—PTGS2—Fluocinonide—Triamcinolone—psoriasis	0.000201	0.0561	CbGdCrCtD
Pomalidomide—TNF—Allograft Rejection—HLA-B—psoriasis	0.000198	0.00312	CbGpPWpGaD
Pomalidomide—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000198	0.00311	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL13—psoriasis	0.000193	0.00304	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.00019	0.003	CbGpPWpGaD
Pomalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriasis	0.000189	0.00298	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000189	0.00297	CbGpPWpGaD
Pomalidomide—TNF—IL23-mediated signaling events—NFKB1—psoriasis	0.000187	0.00294	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—ICAM1—psoriasis	0.000186	0.00293	CbGpPWpGaD
Pomalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000184	0.0029	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—HLA-A—psoriasis	0.000184	0.00289	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL12B—psoriasis	0.000181	0.00285	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—psoriasis	0.000181	0.00284	CbGpPWpGaD
Pomalidomide—PTGS2—S1P1 pathway—VEGFA—psoriasis	0.000179	0.00282	CbGpPWpGaD
Pomalidomide—TNF—Transcription factor regulation in adipogenesis—IL6—psoriasis	0.000178	0.0028	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—psoriasis	0.000177	0.00278	CbGpPWpGaD
Pomalidomide—TNF—Signaling events mediated by HDAC Class I—NFKBIA—psoriasis	0.000176	0.00277	CbGpPWpGaD
Pomalidomide—TNF—FAS pathway and Stress induction of HSP regulation—JUN—psoriasis	0.000175	0.00276	CbGpPWpGaD
Pomalidomide—TNF—TWEAK Signaling Pathway—JUN—psoriasis	0.000175	0.00276	CbGpPWpGaD
Pomalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—LEP—psoriasis	0.000175	0.00275	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—IFNG—psoriasis	0.000174	0.00274	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—APOE—psoriasis	0.000171	0.0027	CbGpPWpGaD
Pomalidomide—TNF—TWEAK Signaling Pathway—NFKB1—psoriasis	0.000169	0.00266	CbGpPWpGaD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—psoriasis	0.000169	0.00266	CbGpPWpGaD
Pomalidomide—TNF—IL23-mediated signaling events—STAT3—psoriasis	0.000168	0.00264	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—HLA-DRB1—psoriasis	0.000168	0.00264	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—IFNG—psoriasis	0.000166	0.00261	CbGpPWpGaD
Pomalidomide—TNF—Signaling events mediated by HDAC Class I—PPARG—psoriasis	0.000164	0.00259	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—psoriasis	0.000164	0.00258	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	0.000163	0.00257	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—CRP—psoriasis	0.000161	0.00253	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	0.000157	0.00247	CbGpPWpGaD
Pomalidomide—TNF—TNF receptor signaling pathway —NFKB1—psoriasis	0.000157	0.00247	CbGpPWpGaD
Pomalidomide—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000157	0.00247	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—SOCS1—psoriasis	0.000156	0.00245	CbGpPWpGaD
Pomalidomide—TNF—IL27-mediated signaling events—IL6—psoriasis	0.000156	0.00245	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000154	0.00242	CbGpPWpGaD
Pomalidomide—PTGS2—Overview of nanoparticle effects—TNF—psoriasis	0.000153	0.00241	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—psoriasis	0.000153	0.0024	CbGpPWpGaD
Pomalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—PPARG—psoriasis	0.000152	0.0024	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—NFKBIA—psoriasis	0.000152	0.00239	CbGpPWpGaD
Pomalidomide—TNF—Ceramide signaling pathway—NFKB1—psoriasis	0.000152	0.00239	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL6—psoriasis	0.000151	0.00238	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—SOCS1—psoriasis	0.000148	0.00233	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—ICAM1—psoriasis	0.000148	0.00232	CbGpPWpGaD
Pomalidomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000147	0.00232	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IL4—psoriasis	0.000147	0.00231	CbGpPWpGaD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—NFKB1—psoriasis	0.000147	0.00231	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.000147	0.00231	CbGpPWpGaD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—psoriasis	0.000146	0.0023	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL13—psoriasis	0.000146	0.0023	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—NFKB1—psoriasis	0.000145	0.00228	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—JUN—psoriasis	0.000144	0.00226	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	0.000143	0.00224	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000142	0.00224	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—IFNG—psoriasis	0.000141	0.00223	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—IFNG—psoriasis	0.000141	0.00223	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—NFKBIA—psoriasis	0.000141	0.00223	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—NFKB1—psoriasis	0.00014	0.00221	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—NFKB1—psoriasis	0.000138	0.00217	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.000138	0.00217	CbGpPWpGaD
Pomalidomide—TNF—Cardiac Hypertrophic Response—NFKB1—psoriasis	0.000136	0.00214	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	0.000136	0.00214	CbGpPWpGaD
Pomalidomide—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	0.000136	0.00214	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL17A—psoriasis	0.000134	0.00211	CbGpPWpGaD
Pomalidomide—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	0.000134	0.0021	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—psoriasis	0.000133	0.0021	CbGpPWpGaD
Pomalidomide—TNF—amb2 Integrin signaling—IL6—psoriasis	0.000132	0.00207	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—NFKBIA—psoriasis	0.00013	0.00205	CbGpPWpGaD
Pomalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000128	0.00202	CbGpPWpGaD
Pomalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—psoriasis	0.000126	0.00198	CbGpPWpGaD
Pomalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—TP53—psoriasis	0.000126	0.00198	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—CAT—psoriasis	0.000125	0.00197	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL12B—psoriasis	0.000125	0.00197	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—LEP—psoriasis	0.000124	0.00196	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—STAT3—psoriasis	0.000124	0.00195	CbGpPWpGaD
Pomalidomide—PTGS2—Fluticasone Propionate—Betamethasone—psoriasis	0.000124	0.0346	CbGdCrCtD
Pomalidomide—PTGS2—Fluticasone Propionate—Dexamethasone—psoriasis	0.000124	0.0346	CbGdCrCtD
Pomalidomide—PTGS2—Overview of nanoparticle effects—IL6—psoriasis	0.000124	0.00195	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—IFNG—psoriasis	0.000122	0.00193	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—JUN—psoriasis	0.000122	0.00192	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—HLA-E—psoriasis	0.000122	0.00192	CbGpPWpGaD
Pomalidomide—PTGS2—Fluticasone Propionate—Triamcinolone—psoriasis	0.000121	0.0338	CbGdCrCtD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL10—psoriasis	0.000121	0.0019	CbGpPWpGaD
Pomalidomide—CYP1A2—Tryptophan metabolism—CAT—psoriasis	0.000119	0.00187	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—NFKB1—psoriasis	0.000118	0.00185	CbGpPWpGaD
Pomalidomide—TNF—IL23-mediated signaling events—IL6—psoriasis	0.000117	0.00185	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—ICAM1—psoriasis	0.000117	0.00184	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—NOS2—psoriasis	0.000116	0.00182	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—LEP—psoriasis	0.000115	0.00181	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—CXCL8—psoriasis	0.000114	0.00179	CbGpPWpGaD
Pomalidomide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000114	0.00179	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—IFNG—psoriasis	0.000112	0.00177	CbGpPWpGaD
Pomalidomide—TNF—Signaling events mediated by HDAC Class I—NFKB1—psoriasis	0.000112	0.00177	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—psoriasis	0.000109	0.00172	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000106	0.00168	CbGpPWpGaD
Pomalidomide—Vertigo—Prednisolone—psoriasis	0.000106	0.000786	CcSEcCtD
Pomalidomide—TNF—TWEAK Signaling Pathway—IL6—psoriasis	0.000106	0.00167	CbGpPWpGaD
Pomalidomide—Infection—Cyclosporine—psoriasis	0.000106	0.00078	CcSEcCtD
Pomalidomide—Back pain—Triamcinolone—psoriasis	0.000105	0.000779	CcSEcCtD
Pomalidomide—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000105	0.00165	CbGpPWpGaD
Pomalidomide—Confusional state—Mycophenolate mofetil—psoriasis	0.000104	0.000772	CcSEcCtD
Pomalidomide—Nervous system disorder—Cyclosporine—psoriasis	0.000104	0.00077	CcSEcCtD
Pomalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—NFKB1—psoriasis	0.000104	0.00164	CbGpPWpGaD
Pomalidomide—Thrombocytopenia—Cyclosporine—psoriasis	0.000104	0.000769	CcSEcCtD
Pomalidomide—Vertigo—Hydrocortisone—psoriasis	0.000104	0.000768	CcSEcCtD
Pomalidomide—Body temperature increased—Mycophenolic acid—psoriasis	0.000104	0.000767	CcSEcCtD
Pomalidomide—Dizziness—Hydroxyurea—psoriasis	0.000104	0.000766	CcSEcCtD
Pomalidomide—Skin disorder—Cyclosporine—psoriasis	0.000103	0.000763	CcSEcCtD
Pomalidomide—Angiopathy—Betamethasone—psoriasis	0.000103	0.000761	CcSEcCtD
Pomalidomide—Angiopathy—Dexamethasone—psoriasis	0.000103	0.000761	CcSEcCtD
Pomalidomide—Infection—Mycophenolate mofetil—psoriasis	0.000103	0.000761	CcSEcCtD
Pomalidomide—Hyperhidrosis—Cyclosporine—psoriasis	0.000103	0.000759	CcSEcCtD
Pomalidomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000103	0.00161	CbGpPWpGaD
Pomalidomide—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000102	0.000751	CcSEcCtD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—NFKBIA—psoriasis	0.000102	0.0016	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—psoriasis	0.000102	0.0016	CbGpPWpGaD
Pomalidomide—Thrombocytopenia—Mycophenolate mofetil—psoriasis	0.000101	0.00075	CcSEcCtD
Pomalidomide—TNF—Signaling events mediated by HDAC Class I—STAT3—psoriasis	0.000101	0.00159	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000101	0.00159	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—JUN—psoriasis	0.000101	0.00159	CbGpPWpGaD
Pomalidomide—Skin disorder—Mycophenolate mofetil—psoriasis	0.000101	0.000744	CcSEcCtD
Pomalidomide—TNF—Adipogenesis—PPARG—psoriasis	0.0001	0.00158	CbGpPWpGaD
Pomalidomide—Hyperhidrosis—Mycophenolate mofetil—psoriasis	0.0001	0.00074	CcSEcCtD
Pomalidomide—Vomiting—Hydroxyurea—psoriasis	9.97e-05	0.000737	CcSEcCtD
Pomalidomide—PTGS2—Selenium Micronutrient Network—CRP—psoriasis	9.93e-05	0.00156	CbGpPWpGaD
Pomalidomide—Rash—Hydroxyurea—psoriasis	9.89e-05	0.000731	CcSEcCtD
Pomalidomide—Dermatitis—Hydroxyurea—psoriasis	9.88e-05	0.00073	CcSEcCtD
Pomalidomide—Headache—Hydroxyurea—psoriasis	9.82e-05	0.000726	CcSEcCtD
Pomalidomide—Anxiety—Hydrocortisone—psoriasis	9.81e-05	0.000725	CcSEcCtD
Pomalidomide—Pancytopenia—Methotrexate—psoriasis	9.8e-05	0.000725	CcSEcCtD
Pomalidomide—Vertigo—Triamcinolone—psoriasis	9.79e-05	0.000723	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	9.78e-05	0.000723	CcSEcCtD
Pomalidomide—Connective tissue disorder—Prednisone—psoriasis	9.72e-05	0.000718	CcSEcCtD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	9.71e-05	0.00153	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—NFKB1—psoriasis	9.7e-05	0.00153	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—NFKB1—psoriasis	9.7e-05	0.00153	CbGpPWpGaD
Pomalidomide—Musculoskeletal discomfort—Cyclosporine—psoriasis	9.68e-05	0.000715	CcSEcCtD
Pomalidomide—Neutropenia—Methotrexate—psoriasis	9.65e-05	0.000713	CcSEcCtD
Pomalidomide—Insomnia—Cyclosporine—psoriasis	9.61e-05	0.00071	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Methotrexate—psoriasis	9.59e-05	0.000709	CcSEcCtD
Pomalidomide—Cough—Triamcinolone—psoriasis	9.5e-05	0.000702	CcSEcCtD
Pomalidomide—Dyspnoea—Cyclosporine—psoriasis	9.47e-05	0.0007	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	9.44e-05	0.000698	CcSEcCtD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—psoriasis	9.44e-05	0.00149	CbGpPWpGaD
Pomalidomide—Asthenia—Mycophenolic acid—psoriasis	9.42e-05	0.000696	CcSEcCtD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	9.38e-05	0.00148	CbGpPWpGaD
Pomalidomide—Infection—Hydrocortisone—psoriasis	9.38e-05	0.000693	CcSEcCtD
Pomalidomide—Insomnia—Mycophenolate mofetil—psoriasis	9.37e-05	0.000693	CcSEcCtD
Pomalidomide—TNF—TNF alpha Signaling Pathway—JUN—psoriasis	9.37e-05	0.00148	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—NFKB1—psoriasis	9.35e-05	0.00147	CbGpPWpGaD
Pomalidomide—Hyperhidrosis—Prednisolone—psoriasis	9.34e-05	0.000691	CcSEcCtD
Pomalidomide—Nausea—Hydroxyurea—psoriasis	9.31e-05	0.000688	CcSEcCtD
Pomalidomide—Pruritus—Mycophenolic acid—psoriasis	9.29e-05	0.000687	CcSEcCtD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—CXCL8—psoriasis	9.28e-05	0.00146	CbGpPWpGaD
Pomalidomide—Nervous system disorder—Hydrocortisone—psoriasis	9.26e-05	0.000684	CcSEcCtD
Pomalidomide—Pneumonia—Methotrexate—psoriasis	9.26e-05	0.000684	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—VEGFA—psoriasis	9.25e-05	0.00146	CbGpPWpGaD
Pomalidomide—Dyspnoea—Mycophenolate mofetil—psoriasis	9.24e-05	0.000683	CcSEcCtD
Pomalidomide—Decreased appetite—Cyclosporine—psoriasis	9.23e-05	0.000682	CcSEcCtD
Pomalidomide—Infestation—Methotrexate—psoriasis	9.2e-05	0.00068	CcSEcCtD
Pomalidomide—Infestation NOS—Methotrexate—psoriasis	9.2e-05	0.00068	CcSEcCtD
Pomalidomide—CYP3A4—Tryptophan metabolism—CAT—psoriasis	9.18e-05	0.00145	CbGpPWpGaD
Pomalidomide—Gastrointestinal disorder—Cyclosporine—psoriasis	9.17e-05	0.000678	CcSEcCtD
Pomalidomide—Skin disorder—Hydrocortisone—psoriasis	9.17e-05	0.000678	CcSEcCtD
Pomalidomide—Fatigue—Cyclosporine—psoriasis	9.16e-05	0.000677	CcSEcCtD
Pomalidomide—PTGS2—Selenium Micronutrient Network—ICAM1—psoriasis	9.13e-05	0.00144	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL10—psoriasis	9.13e-05	0.00144	CbGpPWpGaD
Pomalidomide—Hyperhidrosis—Hydrocortisone—psoriasis	9.13e-05	0.000675	CcSEcCtD
Pomalidomide—PTGS2—Spinal Cord Injury—IL4—psoriasis	9.09e-05	0.00143	CbGpPWpGaD
Pomalidomide—Pain—Cyclosporine—psoriasis	9.08e-05	0.000671	CcSEcCtD
Pomalidomide—Constipation—Cyclosporine—psoriasis	9.08e-05	0.000671	CcSEcCtD
Pomalidomide—TNF—Vitamin B12 Metabolism—IL6—psoriasis	9.08e-05	0.00143	CbGpPWpGaD
Pomalidomide—Renal failure—Methotrexate—psoriasis	9.05e-05	0.000669	CcSEcCtD
Pomalidomide—TNF—TNF alpha Signaling Pathway—NFKB1—psoriasis	9.02e-05	0.00142	CbGpPWpGaD
Pomalidomide—Decreased appetite—Mycophenolate mofetil—psoriasis	9.01e-05	0.000666	CcSEcCtD
Pomalidomide—Diarrhoea—Mycophenolic acid—psoriasis	8.98e-05	0.000664	CcSEcCtD
Pomalidomide—Angiopathy—Prednisone—psoriasis	8.97e-05	0.000663	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	8.95e-05	0.000661	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—IFNG—psoriasis	8.88e-05	0.0014	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL4—psoriasis	8.88e-05	0.0014	CbGpPWpGaD
Pomalidomide—Vertigo—Dexamethasone—psoriasis	8.88e-05	0.000656	CcSEcCtD
Pomalidomide—Vertigo—Betamethasone—psoriasis	8.88e-05	0.000656	CcSEcCtD
Pomalidomide—Pain—Mycophenolate mofetil—psoriasis	8.86e-05	0.000655	CcSEcCtD
Pomalidomide—Constipation—Mycophenolate mofetil—psoriasis	8.86e-05	0.000655	CcSEcCtD
Pomalidomide—Infection—Triamcinolone—psoriasis	8.83e-05	0.000653	CcSEcCtD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	8.82e-05	0.00139	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Cyclosporine—psoriasis	8.75e-05	0.000647	CcSEcCtD
Pomalidomide—Insomnia—Prednisolone—psoriasis	8.74e-05	0.000646	CcSEcCtD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—STAT3—psoriasis	8.72e-05	0.00137	CbGpPWpGaD
Pomalidomide—Hepatobiliary disease—Methotrexate—psoriasis	8.71e-05	0.000643	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—HLA-B—psoriasis	8.69e-05	0.00137	CbGpPWpGaD
Pomalidomide—Dizziness—Mycophenolic acid—psoriasis	8.68e-05	0.000642	CcSEcCtD
Pomalidomide—Epistaxis—Methotrexate—psoriasis	8.68e-05	0.000642	CcSEcCtD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	8.68e-05	0.00137	CbGpPWpGaD
Pomalidomide—Mental disorder—Prednisone—psoriasis	8.66e-05	0.00064	CcSEcCtD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—JUN—psoriasis	8.63e-05	0.00136	CbGpPWpGaD
Pomalidomide—Malnutrition—Prednisone—psoriasis	8.61e-05	0.000636	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Hydrocortisone—psoriasis	8.6e-05	0.000636	CcSEcCtD
Pomalidomide—Hyperhidrosis—Triamcinolone—psoriasis	8.59e-05	0.000635	CcSEcCtD
Pomalidomide—Feeling abnormal—Mycophenolate mofetil—psoriasis	8.54e-05	0.000631	CcSEcCtD
Pomalidomide—Insomnia—Hydrocortisone—psoriasis	8.54e-05	0.000631	CcSEcCtD
Pomalidomide—Body temperature increased—Cyclosporine—psoriasis	8.4e-05	0.000621	CcSEcCtD
Pomalidomide—Anxiety—Dexamethasone—psoriasis	8.38e-05	0.00062	CcSEcCtD
Pomalidomide—Anxiety—Betamethasone—psoriasis	8.38e-05	0.00062	CcSEcCtD
Pomalidomide—Vomiting—Mycophenolic acid—psoriasis	8.35e-05	0.000617	CcSEcCtD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—NFKB1—psoriasis	8.31e-05	0.00131	CbGpPWpGaD
Pomalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—psoriasis	8.29e-05	0.0013	CbGpPWpGaD
Pomalidomide—Rash—Mycophenolic acid—psoriasis	8.28e-05	0.000612	CcSEcCtD
Pomalidomide—TNF—Developmental Biology—CARM1—psoriasis	8.27e-05	0.0013	CbGpPWpGaD
Pomalidomide—Dermatitis—Mycophenolic acid—psoriasis	8.27e-05	0.000611	CcSEcCtD
Pomalidomide—Pain—Prednisolone—psoriasis	8.27e-05	0.000611	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—CXCL8—psoriasis	8.26e-05	0.0013	CbGpPWpGaD
Pomalidomide—Headache—Mycophenolic acid—psoriasis	8.23e-05	0.000608	CcSEcCtD
Pomalidomide—Decreased appetite—Hydrocortisone—psoriasis	8.21e-05	0.000607	CcSEcCtD
Pomalidomide—Body temperature increased—Mycophenolate mofetil—psoriasis	8.19e-05	0.000605	CcSEcCtD
Pomalidomide—Urinary tract disorder—Methotrexate—psoriasis	8.16e-05	0.000603	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Hydrocortisone—psoriasis	8.15e-05	0.000602	CcSEcCtD
Pomalidomide—Fatigue—Hydrocortisone—psoriasis	8.14e-05	0.000602	CcSEcCtD
Pomalidomide—Urethral disorder—Methotrexate—psoriasis	8.1e-05	0.000599	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Triamcinolone—psoriasis	8.1e-05	0.000599	CcSEcCtD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	8.08e-05	0.00127	CbGpPWpGaD
Pomalidomide—Pain—Hydrocortisone—psoriasis	8.07e-05	0.000597	CcSEcCtD
Pomalidomide—TNF—Folate Metabolism—TP53—psoriasis	8.07e-05	0.00127	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—HLA-A—psoriasis	8.05e-05	0.00127	CbGpPWpGaD
Pomalidomide—Insomnia—Triamcinolone—psoriasis	8.04e-05	0.000594	CcSEcCtD
Pomalidomide—Infection—Dexamethasone—psoriasis	8.01e-05	0.000592	CcSEcCtD
Pomalidomide—Infection—Betamethasone—psoriasis	8.01e-05	0.000592	CcSEcCtD
Pomalidomide—Feeling abnormal—Prednisolone—psoriasis	7.97e-05	0.000589	CcSEcCtD
Pomalidomide—Anaemia—Prednisone—psoriasis	7.96e-05	0.000588	CcSEcCtD
Pomalidomide—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	7.95e-05	0.00125	CbGpPWpGaD
Pomalidomide—Dyspnoea—Triamcinolone—psoriasis	7.93e-05	0.000586	CcSEcCtD
Pomalidomide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.91e-05	0.00125	CbGpPWpGaD
Pomalidomide—Nervous system disorder—Dexamethasone—psoriasis	7.91e-05	0.000585	CcSEcCtD
Pomalidomide—Nervous system disorder—Betamethasone—psoriasis	7.91e-05	0.000585	CcSEcCtD
Pomalidomide—Thrombocytopenia—Dexamethasone—psoriasis	7.9e-05	0.000584	CcSEcCtD
Pomalidomide—Thrombocytopenia—Betamethasone—psoriasis	7.9e-05	0.000584	CcSEcCtD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	7.88e-05	0.00124	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Cyclosporine—psoriasis	7.83e-05	0.000578	CcSEcCtD
Pomalidomide—Nausea—Mycophenolic acid—psoriasis	7.8e-05	0.000576	CcSEcCtD
Pomalidomide—Hyperhidrosis—Betamethasone—psoriasis	7.8e-05	0.000576	CcSEcCtD
Pomalidomide—Hyperhidrosis—Dexamethasone—psoriasis	7.8e-05	0.000576	CcSEcCtD
Pomalidomide—Feeling abnormal—Hydrocortisone—psoriasis	7.78e-05	0.000575	CcSEcCtD
Pomalidomide—Vertigo—Prednisone—psoriasis	7.73e-05	0.000571	CcSEcCtD
Pomalidomide—PTGS2—Spinal Cord Injury—LEP—psoriasis	7.69e-05	0.00121	CbGpPWpGaD
Pomalidomide—Cardiac disorder—Methotrexate—psoriasis	7.67e-05	0.000567	CcSEcCtD
Pomalidomide—Fatigue—Triamcinolone—psoriasis	7.66e-05	0.000566	CcSEcCtD
Pomalidomide—Hypersensitivity—Mycophenolate mofetil—psoriasis	7.63e-05	0.000564	CcSEcCtD
Pomalidomide—Asthenia—Cyclosporine—psoriasis	7.62e-05	0.000563	CcSEcCtD
Pomalidomide—Pain—Triamcinolone—psoriasis	7.6e-05	0.000562	CcSEcCtD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—psoriasis	7.56e-05	0.00119	CbGpPWpGaD
Pomalidomide—Pruritus—Cyclosporine—psoriasis	7.52e-05	0.000555	CcSEcCtD
Pomalidomide—Angiopathy—Methotrexate—psoriasis	7.5e-05	0.000554	CcSEcCtD
Pomalidomide—Body temperature increased—Hydrocortisone—psoriasis	7.46e-05	0.000552	CcSEcCtD
Pomalidomide—Mediastinal disorder—Methotrexate—psoriasis	7.45e-05	0.00055	CcSEcCtD
Pomalidomide—Asthenia—Mycophenolate mofetil—psoriasis	7.44e-05	0.000549	CcSEcCtD
Pomalidomide—Chills—Methotrexate—psoriasis	7.41e-05	0.000548	CcSEcCtD
Pomalidomide—TNF—Folate Metabolism—IL6—psoriasis	7.39e-05	0.00116	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	7.35e-05	0.00116	CbGpPWpGaD
Pomalidomide—Musculoskeletal discomfort—Betamethasone—psoriasis	7.35e-05	0.000543	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Dexamethasone—psoriasis	7.35e-05	0.000543	CcSEcCtD
Pomalidomide—Pruritus—Mycophenolate mofetil—psoriasis	7.33e-05	0.000542	CcSEcCtD
Pomalidomide—Arthralgia—Prednisone—psoriasis	7.33e-05	0.000542	CcSEcCtD
Pomalidomide—Feeling abnormal—Triamcinolone—psoriasis	7.33e-05	0.000541	CcSEcCtD
Pomalidomide—Anxiety—Prednisone—psoriasis	7.3e-05	0.00054	CcSEcCtD
Pomalidomide—Insomnia—Dexamethasone—psoriasis	7.3e-05	0.000539	CcSEcCtD
Pomalidomide—Insomnia—Betamethasone—psoriasis	7.3e-05	0.000539	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	7.28e-05	0.000538	CcSEcCtD
Pomalidomide—Diarrhoea—Cyclosporine—psoriasis	7.27e-05	0.000537	CcSEcCtD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—CXCL8—psoriasis	7.25e-05	0.00114	CbGpPWpGaD
Pomalidomide—Mental disorder—Methotrexate—psoriasis	7.24e-05	0.000535	CcSEcCtD
Pomalidomide—PTGS2—Spinal Cord Injury—ICAM1—psoriasis	7.22e-05	0.00114	CbGpPWpGaD
Pomalidomide—Malnutrition—Methotrexate—psoriasis	7.19e-05	0.000532	CcSEcCtD
Pomalidomide—PTGS2—Spinal Cord Injury—NOS2—psoriasis	7.16e-05	0.00113	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Prednisolone—psoriasis	7.12e-05	0.000526	CcSEcCtD
Pomalidomide—Diarrhoea—Mycophenolate mofetil—psoriasis	7.09e-05	0.000524	CcSEcCtD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriasis	7.07e-05	0.00111	CbGpPWpGaD
Pomalidomide—Body temperature increased—Triamcinolone—psoriasis	7.03e-05	0.000519	CcSEcCtD
Pomalidomide—Dizziness—Cyclosporine—psoriasis	7.02e-05	0.000519	CcSEcCtD
Pomalidomide—Decreased appetite—Dexamethasone—psoriasis	7.01e-05	0.000518	CcSEcCtD
Pomalidomide—Decreased appetite—Betamethasone—psoriasis	7.01e-05	0.000518	CcSEcCtD
Pomalidomide—TNF—Alzheimers Disease—TP53—psoriasis	6.99e-05	0.0011	CbGpPWpGaD
Pomalidomide—Infection—Prednisone—psoriasis	6.98e-05	0.000516	CcSEcCtD
Pomalidomide—PTGS2—C-MYB transcription factor network—CD4—psoriasis	6.96e-05	0.0011	CbGpPWpGaD
Pomalidomide—Gastrointestinal disorder—Betamethasone—psoriasis	6.96e-05	0.000515	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Dexamethasone—psoriasis	6.96e-05	0.000515	CcSEcCtD
Pomalidomide—Back pain—Methotrexate—psoriasis	6.96e-05	0.000514	CcSEcCtD
Pomalidomide—Hypersensitivity—Hydrocortisone—psoriasis	6.96e-05	0.000514	CcSEcCtD
Pomalidomide—Fatigue—Dexamethasone—psoriasis	6.95e-05	0.000514	CcSEcCtD
Pomalidomide—Fatigue—Betamethasone—psoriasis	6.95e-05	0.000514	CcSEcCtD
Pomalidomide—PTGS2—Selenium Micronutrient Network—IFNG—psoriasis	6.95e-05	0.00109	CbGpPWpGaD
Pomalidomide—Pain—Dexamethasone—psoriasis	6.9e-05	0.00051	CcSEcCtD
Pomalidomide—Pain—Betamethasone—psoriasis	6.9e-05	0.00051	CcSEcCtD
Pomalidomide—Nervous system disorder—Prednisone—psoriasis	6.89e-05	0.000509	CcSEcCtD
Pomalidomide—Dizziness—Mycophenolate mofetil—psoriasis	6.85e-05	0.000506	CcSEcCtD
Pomalidomide—Skin disorder—Prednisone—psoriasis	6.82e-05	0.000504	CcSEcCtD
Pomalidomide—Hyperhidrosis—Prednisone—psoriasis	6.79e-05	0.000502	CcSEcCtD
Pomalidomide—Asthenia—Hydrocortisone—psoriasis	6.77e-05	0.000501	CcSEcCtD
Pomalidomide—Vomiting—Cyclosporine—psoriasis	6.75e-05	0.000499	CcSEcCtD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—JUN—psoriasis	6.74e-05	0.00106	CbGpPWpGaD
Pomalidomide—Rash—Cyclosporine—psoriasis	6.7e-05	0.000495	CcSEcCtD
Pomalidomide—Dermatitis—Cyclosporine—psoriasis	6.69e-05	0.000495	CcSEcCtD
Pomalidomide—Pruritus—Hydrocortisone—psoriasis	6.68e-05	0.000494	CcSEcCtD
Pomalidomide—Headache—Cyclosporine—psoriasis	6.65e-05	0.000492	CcSEcCtD
Pomalidomide—TNF—Apoptosis—TP53—psoriasis	6.65e-05	0.00105	CbGpPWpGaD
Pomalidomide—Anaemia—Methotrexate—psoriasis	6.65e-05	0.000491	CcSEcCtD
Pomalidomide—Feeling abnormal—Dexamethasone—psoriasis	6.65e-05	0.000491	CcSEcCtD
Pomalidomide—Feeling abnormal—Betamethasone—psoriasis	6.65e-05	0.000491	CcSEcCtD
Pomalidomide—TNF—SIDS Susceptibility Pathways—CXCL8—psoriasis	6.61e-05	0.00104	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	6.61e-05	0.00104	CbGpPWpGaD
Pomalidomide—Vomiting—Mycophenolate mofetil—psoriasis	6.59e-05	0.000487	CcSEcCtD
Pomalidomide—Hypersensitivity—Triamcinolone—psoriasis	6.55e-05	0.000484	CcSEcCtD
Pomalidomide—Rash—Mycophenolate mofetil—psoriasis	6.53e-05	0.000483	CcSEcCtD
Pomalidomide—Dermatitis—Mycophenolate mofetil—psoriasis	6.53e-05	0.000482	CcSEcCtD
Pomalidomide—Headache—Mycophenolate mofetil—psoriasis	6.49e-05	0.00048	CcSEcCtD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—NFKB1—psoriasis	6.48e-05	0.00102	CbGpPWpGaD
Pomalidomide—Vertigo—Methotrexate—psoriasis	6.46e-05	0.000478	CcSEcCtD
Pomalidomide—Diarrhoea—Hydrocortisone—psoriasis	6.46e-05	0.000477	CcSEcCtD
Pomalidomide—Leukopenia—Methotrexate—psoriasis	6.44e-05	0.000476	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Prednisone—psoriasis	6.4e-05	0.000473	CcSEcCtD
Pomalidomide—Dizziness—Prednisolone—psoriasis	6.39e-05	0.000472	CcSEcCtD
Pomalidomide—Asthenia—Triamcinolone—psoriasis	6.38e-05	0.000471	CcSEcCtD
Pomalidomide—Body temperature increased—Betamethasone—psoriasis	6.38e-05	0.000471	CcSEcCtD
Pomalidomide—Body temperature increased—Dexamethasone—psoriasis	6.38e-05	0.000471	CcSEcCtD
Pomalidomide—Insomnia—Prednisone—psoriasis	6.35e-05	0.00047	CcSEcCtD
Pomalidomide—Nausea—Cyclosporine—psoriasis	6.31e-05	0.000466	CcSEcCtD
Pomalidomide—Pruritus—Triamcinolone—psoriasis	6.29e-05	0.000465	CcSEcCtD
Pomalidomide—Cough—Methotrexate—psoriasis	6.28e-05	0.000464	CcSEcCtD
Pomalidomide—Dizziness—Hydrocortisone—psoriasis	6.24e-05	0.000461	CcSEcCtD
Pomalidomide—Nausea—Mycophenolate mofetil—psoriasis	6.16e-05	0.000455	CcSEcCtD
Pomalidomide—TNF—Adipogenesis—STAT3—psoriasis	6.15e-05	0.000968	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—JUN—psoriasis	6.14e-05	0.000967	CbGpPWpGaD
Pomalidomide—Arthralgia—Methotrexate—psoriasis	6.12e-05	0.000453	CcSEcCtD
Pomalidomide—Decreased appetite—Prednisone—psoriasis	6.11e-05	0.000451	CcSEcCtD
Pomalidomide—Rash—Prednisolone—psoriasis	6.09e-05	0.00045	CcSEcCtD
Pomalidomide—Dermatitis—Prednisolone—psoriasis	6.09e-05	0.00045	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	6.08e-05	0.000449	CcSEcCtD
Pomalidomide—Fatigue—Prednisone—psoriasis	6.06e-05	0.000448	CcSEcCtD
Pomalidomide—Headache—Prednisolone—psoriasis	6.06e-05	0.000448	CcSEcCtD
Pomalidomide—Constipation—Prednisone—psoriasis	6.01e-05	0.000444	CcSEcCtD
Pomalidomide—Vomiting—Hydrocortisone—psoriasis	6e-05	0.000444	CcSEcCtD
Pomalidomide—Rash—Hydrocortisone—psoriasis	5.95e-05	0.00044	CcSEcCtD
Pomalidomide—Dermatitis—Hydrocortisone—psoriasis	5.95e-05	0.00044	CcSEcCtD
Pomalidomide—Confusional state—Methotrexate—psoriasis	5.92e-05	0.000437	CcSEcCtD
Pomalidomide—Headache—Hydrocortisone—psoriasis	5.91e-05	0.000437	CcSEcCtD
Pomalidomide—TNF—SIDS Susceptibility Pathways—NFKB1—psoriasis	5.91e-05	0.000931	CbGpPWpGaD
Pomalidomide—Dizziness—Triamcinolone—psoriasis	5.88e-05	0.000434	CcSEcCtD
Pomalidomide—TNF—Selenium Micronutrient Network—IL6—psoriasis	5.87e-05	0.000924	CbGpPWpGaD
Pomalidomide—Infection—Methotrexate—psoriasis	5.83e-05	0.000431	CcSEcCtD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	5.8e-05	0.000913	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—JUN—psoriasis	5.79e-05	0.000911	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Prednisone—psoriasis	5.79e-05	0.000428	CcSEcCtD
Pomalidomide—Asthenia—Betamethasone—psoriasis	5.79e-05	0.000428	CcSEcCtD
Pomalidomide—Asthenia—Dexamethasone—psoriasis	5.79e-05	0.000428	CcSEcCtD
Pomalidomide—PTGS2—Selenium Micronutrient Network—NFKB1—psoriasis	5.78e-05	0.00091	CbGpPWpGaD
Pomalidomide—Nervous system disorder—Methotrexate—psoriasis	5.76e-05	0.000425	CcSEcCtD
Pomalidomide—Thrombocytopenia—Methotrexate—psoriasis	5.75e-05	0.000425	CcSEcCtD
Pomalidomide—Nausea—Prednisolone—psoriasis	5.74e-05	0.000424	CcSEcCtD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	5.71e-05	0.000899	CbGpPWpGaD
Pomalidomide—Pruritus—Betamethasone—psoriasis	5.71e-05	0.000422	CcSEcCtD
Pomalidomide—Pruritus—Dexamethasone—psoriasis	5.71e-05	0.000422	CcSEcCtD
Pomalidomide—Skin disorder—Methotrexate—psoriasis	5.7e-05	0.000421	CcSEcCtD
Pomalidomide—Hyperhidrosis—Methotrexate—psoriasis	5.68e-05	0.000419	CcSEcCtD
Pomalidomide—TNF—TNF alpha Signaling Pathway—IL6—psoriasis	5.66e-05	0.000891	CbGpPWpGaD
Pomalidomide—Vomiting—Triamcinolone—psoriasis	5.65e-05	0.000418	CcSEcCtD
Pomalidomide—Nausea—Hydrocortisone—psoriasis	5.61e-05	0.000414	CcSEcCtD
Pomalidomide—Rash—Triamcinolone—psoriasis	5.6e-05	0.000414	CcSEcCtD
Pomalidomide—Dermatitis—Triamcinolone—psoriasis	5.6e-05	0.000414	CcSEcCtD
Pomalidomide—TNF—MAPK Signaling Pathway—NFKB1—psoriasis	5.57e-05	0.000877	CbGpPWpGaD
Pomalidomide—Headache—Triamcinolone—psoriasis	5.57e-05	0.000412	CcSEcCtD
Pomalidomide—Body temperature increased—Prednisone—psoriasis	5.55e-05	0.00041	CcSEcCtD
Pomalidomide—Diarrhoea—Betamethasone—psoriasis	5.52e-05	0.000408	CcSEcCtD
Pomalidomide—Diarrhoea—Dexamethasone—psoriasis	5.52e-05	0.000408	CcSEcCtD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	5.5e-05	0.000865	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IFNG—psoriasis	5.49e-05	0.000865	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IFNG—psoriasis	5.37e-05	0.000845	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—VEGFA—psoriasis	5.37e-05	0.000845	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	5.36e-05	0.000844	CbGpPWpGaD
Pomalidomide—Musculoskeletal discomfort—Methotrexate—psoriasis	5.35e-05	0.000395	CcSEcCtD
Pomalidomide—Dizziness—Betamethasone—psoriasis	5.33e-05	0.000394	CcSEcCtD
Pomalidomide—Dizziness—Dexamethasone—psoriasis	5.33e-05	0.000394	CcSEcCtD
Pomalidomide—Insomnia—Methotrexate—psoriasis	5.31e-05	0.000392	CcSEcCtD
Pomalidomide—Nausea—Triamcinolone—psoriasis	5.28e-05	0.00039	CcSEcCtD
Pomalidomide—Dyspnoea—Methotrexate—psoriasis	5.23e-05	0.000387	CcSEcCtD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	5.22e-05	0.000822	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—IL6—psoriasis	5.21e-05	0.000821	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Prednisone—psoriasis	5.18e-05	0.000382	CcSEcCtD
Pomalidomide—Vomiting—Dexamethasone—psoriasis	5.13e-05	0.000379	CcSEcCtD
Pomalidomide—Vomiting—Betamethasone—psoriasis	5.13e-05	0.000379	CcSEcCtD
Pomalidomide—PTGS2—Spinal Cord Injury—CXCL8—psoriasis	5.11e-05	0.000804	CbGpPWpGaD
Pomalidomide—Decreased appetite—Methotrexate—psoriasis	5.1e-05	0.000377	CcSEcCtD
Pomalidomide—Rash—Dexamethasone—psoriasis	5.09e-05	0.000376	CcSEcCtD
Pomalidomide—Rash—Betamethasone—psoriasis	5.09e-05	0.000376	CcSEcCtD
Pomalidomide—Dermatitis—Dexamethasone—psoriasis	5.08e-05	0.000376	CcSEcCtD
Pomalidomide—Dermatitis—Betamethasone—psoriasis	5.08e-05	0.000376	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—TP53—psoriasis	5.07e-05	0.000798	CbGpPWpGaD
Pomalidomide—Gastrointestinal disorder—Methotrexate—psoriasis	5.07e-05	0.000375	CcSEcCtD
Pomalidomide—Fatigue—Methotrexate—psoriasis	5.06e-05	0.000374	CcSEcCtD
Pomalidomide—Headache—Dexamethasone—psoriasis	5.05e-05	0.000373	CcSEcCtD
Pomalidomide—Headache—Betamethasone—psoriasis	5.05e-05	0.000373	CcSEcCtD
Pomalidomide—Asthenia—Prednisone—psoriasis	5.04e-05	0.000372	CcSEcCtD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	5.03e-05	0.000792	CbGpPWpGaD
Pomalidomide—Pain—Methotrexate—psoriasis	5.02e-05	0.000371	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—CXCL8—psoriasis	4.99e-05	0.000786	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	4.99e-05	0.000785	CbGpPWpGaD
Pomalidomide—Pruritus—Prednisone—psoriasis	4.97e-05	0.000367	CcSEcCtD
Pomalidomide—PTGS2—Metabolism—NDUFA5—psoriasis	4.9e-05	0.000771	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	4.87e-05	0.000767	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Methotrexate—psoriasis	4.84e-05	0.000358	CcSEcCtD
Pomalidomide—Diarrhoea—Prednisone—psoriasis	4.81e-05	0.000355	CcSEcCtD
Pomalidomide—Nausea—Dexamethasone—psoriasis	4.79e-05	0.000354	CcSEcCtD
Pomalidomide—Nausea—Betamethasone—psoriasis	4.79e-05	0.000354	CcSEcCtD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	4.68e-05	0.000737	CbGpPWpGaD
Pomalidomide—Dizziness—Prednisone—psoriasis	4.65e-05	0.000343	CcSEcCtD
Pomalidomide—Body temperature increased—Methotrexate—psoriasis	4.64e-05	0.000343	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—IL6—psoriasis	4.64e-05	0.00073	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.57e-05	0.000719	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	4.56e-05	0.000718	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—TNF—psoriasis	4.5e-05	0.000708	CbGpPWpGaD
Pomalidomide—Vomiting—Prednisone—psoriasis	4.47e-05	0.00033	CcSEcCtD
Pomalidomide—Rash—Prednisone—psoriasis	4.43e-05	0.000327	CcSEcCtD
Pomalidomide—Dermatitis—Prednisone—psoriasis	4.42e-05	0.000327	CcSEcCtD
Pomalidomide—Headache—Prednisone—psoriasis	4.4e-05	0.000325	CcSEcCtD
Pomalidomide—Hypersensitivity—Methotrexate—psoriasis	4.33e-05	0.00032	CcSEcCtD
Pomalidomide—TNF—Adipogenesis—IL6—psoriasis	4.29e-05	0.000676	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	4.28e-05	0.000673	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	4.28e-05	0.000673	CbGpPWpGaD
Pomalidomide—Asthenia—Methotrexate—psoriasis	4.21e-05	0.000311	CcSEcCtD
Pomalidomide—Nausea—Prednisone—psoriasis	4.17e-05	0.000308	CcSEcCtD
Pomalidomide—PTGS2—Metabolism—CYP2S1—psoriasis	4.17e-05	0.000656	CbGpPWpGaD
Pomalidomide—Pruritus—Methotrexate—psoriasis	4.15e-05	0.000307	CcSEcCtD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	4.11e-05	0.000647	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—psoriasis	4.08e-05	0.000642	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL6—psoriasis	4.07e-05	0.000641	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—VEGFA—psoriasis	4.05e-05	0.000638	CbGpPWpGaD
Pomalidomide—Diarrhoea—Methotrexate—psoriasis	4.02e-05	0.000297	CcSEcCtD
Pomalidomide—TNF—Developmental Biology—LEP—psoriasis	3.95e-05	0.000622	CbGpPWpGaD
Pomalidomide—Dizziness—Methotrexate—psoriasis	3.88e-05	0.000287	CcSEcCtD
Pomalidomide—TNF—MAPK Signaling Pathway—TP53—psoriasis	3.82e-05	0.000602	CbGpPWpGaD
Pomalidomide—Vomiting—Methotrexate—psoriasis	3.73e-05	0.000276	CcSEcCtD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL6—psoriasis	3.71e-05	0.000584	CbGpPWpGaD
Pomalidomide—Rash—Methotrexate—psoriasis	3.7e-05	0.000274	CcSEcCtD
Pomalidomide—Dermatitis—Methotrexate—psoriasis	3.7e-05	0.000273	CcSEcCtD
Pomalidomide—Headache—Methotrexate—psoriasis	3.68e-05	0.000272	CcSEcCtD
Pomalidomide—PTGS2—Selenium Micronutrient Network—IL6—psoriasis	3.63e-05	0.000571	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TNF—psoriasis	3.56e-05	0.00056	CbGpPWpGaD
Pomalidomide—Nausea—Methotrexate—psoriasis	3.49e-05	0.000258	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—TNF—psoriasis	3.48e-05	0.000547	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NDUFA5—psoriasis	3.47e-05	0.000547	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	3.45e-05	0.000544	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	3.45e-05	0.000543	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—PPARG—psoriasis	3.44e-05	0.000542	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	3.23e-05	0.000509	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	3.23e-05	0.000508	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TP53—psoriasis	3.14e-05	0.000494	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	3.11e-05	0.00049	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	3.08e-05	0.000485	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—TYK2—psoriasis	3.02e-05	0.000475	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP2S1—psoriasis	2.95e-05	0.000465	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL6—psoriasis	2.87e-05	0.000452	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	2.82e-05	0.000444	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NDUFA5—psoriasis	2.77e-05	0.000437	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.59e-05	0.000407	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	2.42e-05	0.000381	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP2S1—psoriasis	2.36e-05	0.000371	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—NFKB1—psoriasis	2.35e-05	0.00037	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.29e-05	0.000361	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.2e-05	0.000347	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.18e-05	0.000344	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NDUFA5—psoriasis	2.14e-05	0.000337	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—VEGFA—psoriasis	2.13e-05	0.000336	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	2.13e-05	0.000336	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—STAT3—psoriasis	2.11e-05	0.000333	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CARM1—psoriasis	2.04e-05	0.00032	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	2e-05	0.000315	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.9e-05	0.000299	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP2S1—psoriasis	1.82e-05	0.000286	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.71e-05	0.00027	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.51e-05	0.000238	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—IL6—psoriasis	1.48e-05	0.000232	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CARM1—psoriasis	1.44e-05	0.000227	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CAT—psoriasis	1.25e-05	0.000197	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HLA-A—psoriasis	1.24e-05	0.000196	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.24e-05	0.000195	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—APOE—psoriasis	1.16e-05	0.000183	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CARM1—psoriasis	1.15e-05	0.000181	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NOS2—psoriasis	1.08e-05	0.00017	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.08e-05	0.000169	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—APOE—psoriasis	9.73e-06	0.000153	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CARM1—psoriasis	8.89e-06	0.00014	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CAT—psoriasis	8.87e-06	0.00014	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TYK2—psoriasis	8.86e-06	0.00014	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PPARG—psoriasis	8.47e-06	0.000133	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CD4—psoriasis	8.02e-06	0.000126	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CAT—psoriasis	7.08e-06	0.000112	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—APOE—psoriasis	6.89e-06	0.000109	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—STAT3—psoriasis	6.21e-06	9.77e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PPARG—psoriasis	6.01e-06	9.45e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—APOE—psoriasis	5.5e-06	8.66e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CAT—psoriasis	5.47e-06	8.61e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PPARG—psoriasis	4.79e-06	7.55e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—IL6—psoriasis	4.34e-06	6.82e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—APOE—psoriasis	4.25e-06	6.69e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PPARG—psoriasis	3.7e-06	5.82e-05	CbGpPWpGaD
